U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07025018) titled 'Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations' on May 28.
Brief Summary: This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Gliomas Harboring IDH1 and/or IDH2 Mutations
Intervention:
DRUG: HMPL-306
IDH small molecule inhibitor
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hutchmed
Published by HT Digital Content Services w...